Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Quantin

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|April 5, 2001
Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factorsW Jacot, X Quantin, J M Boher, et al.
British Journal of Cancer|September 1, 1996
Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancersJ L Pujol, J Simony, G Jolimoy, et al.
Revue Des Maladies Respiratoires|August 5, 1998
[Biological perspectives]J L Pujol, P Demoly, X Quantin, et al.
Journal of the National Cancer Institute|February 22, 2001
Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized studyJ L Pujol, J P Daurès, A Rivière, et al.
La Revue De Medecine Interne|January 24, 2021
[Management of immune-related toxicities associated with immune checkpoints inhibitors: Data from the multidisciplinary meeting « ToxImmun » in Eastern Occitania]V Rivet, X Quantin, J L Faillie, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2023
Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitorsP E Heudel, A de Montfort, D Debieuvre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2005
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatinJ-L Pujol, J-L Breton, R Gervais, et al.
ESMO Open|July 24, 2025
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysisK Amrane, B Cabarrou, G Justeau, et al.
ESMO Open|June 4, 2024
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohortQ D Thomas, X Quantin, P Lemercier, et al.
Clinical Lung Cancer|March 19, 2021
RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical ResectionC Basse, A Botticella, T J Molina, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|April 5, 2001
Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factorsW Jacot, X Quantin, J M Boher, et al.
British Journal of Cancer|September 1, 1996
Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancersJ L Pujol, J Simony, G Jolimoy, et al.
Revue Des Maladies Respiratoires|August 5, 1998
[Biological perspectives]J L Pujol, P Demoly, X Quantin, et al.
Journal of the National Cancer Institute|February 22, 2001
Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized studyJ L Pujol, J P Daurès, A Rivière, et al.
La Revue De Medecine Interne|January 24, 2021
[Management of immune-related toxicities associated with immune checkpoints inhibitors: Data from the multidisciplinary meeting « ToxImmun » in Eastern Occitania]V Rivet, X Quantin, J L Faillie, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2023
Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitorsP E Heudel, A de Montfort, D Debieuvre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2005
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatinJ-L Pujol, J-L Breton, R Gervais, et al.
ESMO Open|July 24, 2025
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysisK Amrane, B Cabarrou, G Justeau, et al.
ESMO Open|June 4, 2024
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohortQ D Thomas, X Quantin, P Lemercier, et al.
Clinical Lung Cancer|March 19, 2021
RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical ResectionC Basse, A Botticella, T J Molina, et al.
Pageof 5